Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Theranostics|June 3, 2020
Hepatoma cell-intrinsic TLR9 activation induces immune escape through PD-L1 upregulation in hepatocellular carcinomaBinghai Zhou, Jiuliang Yan, Lei Guo, et al.
Frontiers in Immunology|April 12, 2021
PNOC Expressed by B Cells in Cholangiocarcinoma Was Survival Related and LAIR2 Could Be a T Cell Exhaustion Biomarker in Tumor Microenvironment: Characterization of Immune Microenvironment Combining Single-Cell and Bulk Sequencing TechnologyZheng Chen, Mincheng Yu, Jiuliang Yan, et al.
Oncoimmunology|July 11, 2024
SIGLEC15, negatively correlated with PD-L1 in HCC, could induce CD8+ T cell apoptosis to promote immune evasionZheng Chen, Mincheng Yu, Bo Zhang, et al.
Science Advances|August 22, 2025
Liver regeneration-associated hepatocellular YAP1 activation prevents colorectal cancer liver metastasis through glutamine competitionQiang Yu, Mincheng Yu, Peiyi Xie, et al.
Cancer Research|November 4, 2024
ACE2 Enhances Sensitivity to PD-L1 Blockade by Inhibiting Macrophage-Induced Immunosuppression and AngiogenesisPeiyi Xie, Lei Guo, Qiang Yu, et al.
Journal of Hepatology|February 25, 2024
CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinomaPeiyi Xie, Mincheng Yu, Bo Zhang, et al.
The Lancet. Gastroenterology & Hepatology|November 30, 2025
Adjuvant camrelizumab combined with capecitabine in patients with intrahepatic cholangiocarcinoma after surgical resection in China (ACC): a single-arm, single-centre, open-label, phase 2 trialZheng Wang, Lixing Li, Peiran Huang, et al.
Journal of Hepatology|February 14, 2022
PARG inhibition limits HCC progression and potentiates the efficacy of immune checkpoint therapyMincheng Yu, Zheng Chen, Qiang Zhou, et al.
Therapeutic Advances in Neurological Disorders|April 15, 2024
Treatment algorithms of relapsing multiple sclerosis: an exploration based on the available disease-modifying therapies in ChinaJun Guo, Jiayong Wu, Lihua Wang, et al.
The Lancet. Oncology|September 1, 2025
Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 studyGuoming Shi, Xiaoyong Huang, Xiaowu Li, et al.
Pageof 9